RCELHealthcare · Medical DevicesThe 3 Wall Street analysts covering AVITA Medical, Inc. hold a median 12-month price target of $12 — -12.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 8 Oct 2026 — in the upper half. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores AVITA Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RCEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −12.7% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Aug 2026 | Lake Street | Maintains | Buy | $8.00 → $12 |
| 19 Aug 2026 | BTIG | Maintains | Buy | $7.00 → $11 |
| 19 Aug 2026 | BTIG | Maintains | Buy | — |
| 19 Aug 2026 | TD Cowen | Maintains | Buy | $12 → $14 |
| 19 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 7 Aug 2026 | BTIG | Upgrade | Buy | — |
| 7 Aug 2026 | BTIG | Upgrade | Buy | $7.00 |
| 15 May 2026 | Lake Street | Upgrade | Buy | $3.50 → $6.00 |
| 15 May 2026 | Lake Street | Upgrade | Buy | — |
| 9 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Mar 2026 | Northland Capital Markets | Initiates | Outperform | — |
| 17 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 26 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 16 Jan 2026 | Lake Street | Maintains | Hold | — |
| 15 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 20 Nov 2025 | BTIG | Upgrade | Neutral | — |
| 7 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 Oct 2025 | Lake Street | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RCEL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, AVITA Medical, Inc. returned +141.9% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 23% of US stocks
Cheaper than 98% of US stocks
Cheaper than 87% of US stocks
Higher than 66% of US stocks
Higher than 56% of US stocks
Higher than 92% of US stocks
Higher than 19% of US stocks
Higher than 9% of US stocks
Higher than 99% of US stocks
Higher than 10% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AVITA Medical, Inc. has a market value of $403.6M and an enterprise value of $440.9M.
Revenue in the twelve months to 30 June 2026: $75.6M. The latest quarter grew 17.8% year on year.
Net income over the same four quarters: −$43.1M, a −57.0% net margin.
Diluted earnings per share, trailing twelve months: $−1.44.
Free cash flow in the twelve months to 30 June 2026: −$25.3M.
Trailing P/E: −7.3×; forward P/E: −30.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
AVITA Medical, Inc. employs 226 people — $335K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AVITA Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
AVITA Medical, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference. A transcript of the company's presentation at the conference was published.
Why it matters — The presentation gives RCEL watchers direct insight into the company's latest positioning and messaging to the investment community.
AVITA Medical announced that its senior management will participate in two upcoming investor conferences: the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10, 2026 in New York, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, with investor meetings featuring CEO Cary Vance and CFO David O'Toole.
Why it matters — RCEL watchers would care because the company's leadership will present and hold investor meetings at two major industry conferences, offering exposure to institutional investors.
Zacks Investment Research upgraded Avita Medical (RCEL) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The upgrade reflects a more favorable view of RCEL's near-term outlook.
Why it matters — A Zacks upgrade to a Buy rank signals increased analyst confidence in RCEL's earnings trajectory, which RCEL watchers watch closely as an indicator of expected share-price movement.
Zacks Investment Research published an analysis examining whether Avita Medical Inc. (RCEL) qualifies as a strong momentum stock for investors. The piece poses the question of whether the company has what it takes to become a top momentum pick.
Why it matters — A momentum-focused assessment can influence how investors perceive RCEL's recent price and earnings trends, making it relevant for those tracking the stock's market position.
AVITA Medical's reimbursement is becoming more predictable, removing a key adoption barrier for its skin wound care products. The RECELL GO international rollout and PermeaDerm's positive clinical economics are broadening the company's long-term potential, while management expects to reach its cash flow breakeven target by Q4 2026.
Why it matters — For RCEL watchers, more predictable reimbursement and an on-track cash flow breakeven target could reduce a key adoption barrier and help derisk the company's outlook.
The 3 Wall Street analysts covering AVITA Medical, Inc. have a median 12-month price target of $12, with estimates ranging from $11 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering AVITA Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AVITA Medical, Inc. 73 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, AVITA Medical, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies -12.7% from the last close, and Ticker Nerd's factor model ranks AVITA Medical, Inc. 73 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AVITA Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $14 over the next 12 months.
AVITA Medical, Inc. returned +141.9% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
AVITA Medical, Inc. is a therapeutic acute wound care company focused on regenerative solutions for skin restoration and wound healing.
The most recent item we track (Seeking Alpha, 16 Sept 2026): "AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". AVITA Medical, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference. A transcript of the company's presentation at the conference was published.
AVITA Medical, Inc. is a therapeutic acute wound care company focused on regenerative solutions for skin restoration and wound healing. Its flagship RECELL System uses a patient’s own skin cells to create a spray-on cell suspension at the point of care for the treatment of thermal burn wounds, full-thickness skin defects, and stable depigmented vitiligo lesions. The company also markets PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix, supporting surgeons and clinicians in burn care, trauma care, and reconstructive procedures. AVITA Medical serves hospitals, treatment centers, and distributors across the United States, Japan, the European Union, Australia, and the United Kingdom. Headquartered in Valencia, California, AVITA Medical specializes in technologies designed to improve wound coverage and support clinical recovery in acute care settings.
CEO Mr. Cary G. Vance · 226 employees · United States · https://avitamedical.com
